Eli Lilly upgrades earnings per share guidance

US-based pharmaceutical company Eli Lilly has presented results from the third quarter of 2021, and in connection with the release, expectations for earnings per share have been adjusted.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
US court orders Eli Lilly to pay royalties on diabetes drugs
For subscribers